ID   YP-MEL
AC   CVCL_L217
DR   Wikidata; Q54995472
RX   PubMed=7520166;
RX   PubMed=9290701;
CC   Population: Japanese.
CC   Doubling time: 41 hours (PubMed=7520166).
CC   Derived from site: Metastatic; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   4Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 29-06-23; Version: 8
//
RX   PubMed=7520166; DOI=10.1016/S0344-0338(11)80709-0;
RA   Nagashima, Yoji
RA   Miyagi, Yohei
RA   Aoki, Ichiro
RA   Funabiki, Tetsunori
RA   Ikuta, Koichiro
RA   Umeda, Makoto
RA   Kuchino, Yoshiyuki
RA   Misugi, Kazuaki
RT   "Establishment and characterization of a malignant melanoma cell line
RT   (YP-MEL) derived from a patient with neurocutaneous melanosis.";
RL   Pathol. Res. Pract. 190:178-185(1994).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia, Li-Qun
RA   Osada, Motonobu
RA   Ishioka, Chikashi
RA   Gamo, Makio
RA   Ikawa, Shuntaro
RA   Suzuki, Takao
RA   Shimodaira, Hideki
RA   Niitani, Tomohito
RA   Kudo, Toshio
RA   Akiyama, Mitoshi
RA   Kimura, Narimiti
RA   Matsuo, Mitsuyoshi
RA   Mizusawa, Hiroshi
RA   Tanaka, Noriho
RA   Koyama, Hideki
RA   Namba, Masayoshi
RA   Kanamaru, Ryunosuke
RA   Kuroki, Toshio
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//